Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Bacac

Showing results (21-30 of 79) with videos related to

Pageof 8
Sort By:
Nature Communications|July 22, 2025
Resolving the structural basis of therapeutic antibody function in cancer immunotherapy with RESIIsabelle Pachmayr, Luciano A Masullo, Susanne C M Reinhardt, et al.
Plos One|January 6, 2021
Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine modelFloriana Cremasco, Elena Menietti, Dario Speziale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2015
Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance EfficacyValeria Gonzalez-Nicolini, Sylvia Herter, Sabine Lang, et al.
The AAPS Journal|December 4, 2021
A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data AnalysisArthur Van De Vyver, Miro Eigenmann, Meric Ovacik, et al.
Haematologica|October 29, 2017
GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activitySylvia Herter, Frank Herting, Gunter Muth, et al.
Journal of Pharmaceutical Sciences|December 26, 2021
Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for GlofitamabNicolas Frances, Marina Bacac, Katharine Bray-French, et al.
Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry|March 23, 2004
Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2]Anna C G Hotze, Sabrine E Caspers, Dick de Vos, et al.
Cancer Immunology, Immunotherapy : CII|November 19, 2016
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agentsSylvia Herter, Laura Morra, Ramona Schlenker, et al.
Frontiers in Immunology|August 23, 2021
Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor ImmunityCaleb R Stoltzfus, Ramya Sivakumar, Leo Kunz, et al.
Blood Advances|January 22, 2026
Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell LymphomaStephan Schmeing, Sina Nassiri, Gabrielle Leclercq-Cohen, et al.
Pageof 8

Showing results (21-30 of 79) with videos related to

Sort By:
Pageof 8
Nature Communications|July 22, 2025
Resolving the structural basis of therapeutic antibody function in cancer immunotherapy with RESIIsabelle Pachmayr, Luciano A Masullo, Susanne C M Reinhardt, et al.
Plos One|January 6, 2021
Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine modelFloriana Cremasco, Elena Menietti, Dario Speziale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2015
Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance EfficacyValeria Gonzalez-Nicolini, Sylvia Herter, Sabine Lang, et al.
The AAPS Journal|December 4, 2021
A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data AnalysisArthur Van De Vyver, Miro Eigenmann, Meric Ovacik, et al.
Haematologica|October 29, 2017
GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activitySylvia Herter, Frank Herting, Gunter Muth, et al.
Journal of Pharmaceutical Sciences|December 26, 2021
Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for GlofitamabNicolas Frances, Marina Bacac, Katharine Bray-French, et al.
Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry|March 23, 2004
Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2]Anna C G Hotze, Sabrine E Caspers, Dick de Vos, et al.
Cancer Immunology, Immunotherapy : CII|November 19, 2016
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agentsSylvia Herter, Laura Morra, Ramona Schlenker, et al.
Frontiers in Immunology|August 23, 2021
Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor ImmunityCaleb R Stoltzfus, Ramya Sivakumar, Leo Kunz, et al.
Blood Advances|January 22, 2026
Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell LymphomaStephan Schmeing, Sina Nassiri, Gabrielle Leclercq-Cohen, et al.
Pageof 8